The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans

Pharmacogenetics and Genomics

Volumn 21, Issue 2, 2011, Pages 84-93

  Imanaga, Junko ^a   Kotegawa, Tsutomu ^a   Imai, Hiromitsu ^a   Tsutsumi, Kimiko ^a   Yoshizato, Tsuneaki ^a   Ohyama, Tetsuji ^a   Shirasaka, Yoshiyuki ^b   Tamai, Ikumi ^b   Tateishi, Tomonori ^c   Ohashi, Kyoichi ^a  

^a OITA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

apple juice; fexofenadine; midazolam; SLCO2B1

Indexed keywords

FEXOFENADINE; MIDAZOLAM; MIDAZOLAM MALEATE; ORGANIC ANION TRANSPORTER; RNA; SLCO2B1 PROTEIN; UNCLASSIFIED DRUG; WATER;

ADULT; ALLELE; ANIMAL CELL; APPLE JUICE; ARTICLE; CROSSOVER PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RETENTION; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION SYSTEM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; XENOPUS LAEVIS;

ADULT; ANIMALS; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL TRANSPORT; GABA MODULATORS; HUMANS; MALE; MALUS; MIDAZOLAM; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; TERFENADINE; XENOPUS LAEVIS; YOUNG ADULT;

MALUS X DOMESTICA; XENOPUS LAEVIS;

EID: 78751614878     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834300cc     Document Type: Article

References (26)

1. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46:101-110.
2. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003; 33:10-16.
3. Farkas D, Greenbalatt DJ. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008; 4:381-393.
4. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158:693-705.
5. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81:362-370.
6. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273:251-260.
7. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71:11-20.
8. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308:438-445.
9. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33:518-523.
10. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302:804-813.
11. Gorski JC, Hall SD, Jones DR, Vanden Branden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-1653.
12. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96.
13. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16:408-414.
14. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2009; 84:704-709.
15. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26:2039-2054.
16. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Ta m a i I, et al. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 2010; 332:181-189.
17. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal 2004; 35:937-942.
18. Arendt RM, Greenblatt DJ, Garland WA. Quantitation by gas chromatography of the 1-and 4-hydrozy metabolites of midazolam in human plasma. Pharmacology 1984; 29:158-164.
19. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005; 33:1477-1481.
20. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129-138.
21. Aoki M, Terada T, Ogasawara K, Katsura T, Hatano E, Ikai I, et al. Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet Genomics 2009; 19:647-656.
22. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drug on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2009; 36:663-669.
23. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81: 495-502.
24. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66:461-471.
25. Greenblatt DJ, Von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003; 74:121-129.
26. Garrett M, Smeraglia J, Lin X, Tan L, Tran J. A pilot study to assess simultaneous administration of oral midazolam (MDZ) and fexofenadine (FEX) for the evaluation of cytochrome (CYP) 3A4 and P-glycoprotein (P-gp) activities. Clin Pharmacol Ther 2005; 77:45.